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1. INTRODUCTION {#cas14331-sec-0001}
===============

Hepatocellular carcinoma (HCC) is the fifth most common type of malignant tumor and a leading cause of cancer‐related death worldwide.[1](#cas14331-bib-0001){ref-type="ref"} HCC is a complex malignancy with various genetic abnormalities. Although HCC patients can be treated by surgical resection, radiotherapy and/or sorafenib, many HCC patients die due to recurrence, metastasis and blood vessel invasion.[2](#cas14331-bib-0002){ref-type="ref"}, [3](#cas14331-bib-0003){ref-type="ref"}, [4](#cas14331-bib-0004){ref-type="ref"} Therefore, exploring the molecular mechanism of HCC tumorigenesis and metastasis may help to understand the pathogenesis of HCC and to find potential molecular targets for treatment of this malignancy.

Epithelial V‐like antigen (EVA) 1 was originally identified as a member of the immunoglobulin superfamily expressed on the membrane of developing thymus epithelial cells and was strongly downregulated during thymocyte developmental progression.[5](#cas14331-bib-0005){ref-type="ref"}, [6](#cas14331-bib-0006){ref-type="ref"}, [7](#cas14331-bib-0007){ref-type="ref"} It is highly homologous to the myelin protein zero and is also referred to as MPZL2. The EVA1 protein bears a characteristic V‐type domain and two potential N‐glycosylation sites at the extracellular domain. Several studies have indicated that EVA1 may have a role in certain malignancies, including lung,[8](#cas14331-bib-0008){ref-type="ref"}, [9](#cas14331-bib-0009){ref-type="ref"} papillary thyroid[10](#cas14331-bib-0010){ref-type="ref"} and breast cancers.[11](#cas14331-bib-0011){ref-type="ref"}, [12](#cas14331-bib-0012){ref-type="ref"} Ohtsu and collegues[13](#cas14331-bib-0013){ref-type="ref"} report that EVA1 might be responsible for maintaining the stem‐like character of glioblastoma‐initiating cells, by activating the noncanonical NF‐κB signaling cascade. However, a role of EVA1 in HCC progression has not been investigated yet. In the present work, we reveal that HCC patients with high EVA1 expression have a poor prognosis and high recurrence. Furthermore, we find that EVA1 promotes cell growth and migration in vitro, while inducing metastasis in vivo. Using RNA‐seq analyses, we reveal that EVA1 potentially accelerates HCC progression via ERBB‐PI3K‐AKT signaling. The present study reveals the function and underlying mechanisms of EVA1 in HCC, providing important insights for a potential therapeutic target and prognostic marker for this malignancy.

2. MATERIALS AND METHODS {#cas14331-sec-0002}
========================

2.1. Reagents {#cas14331-sec-0003}
-------------

Epithelial V‐like antigen 1 EVA1 and GAPDH antibodies were acquired from Proteintech (11787‐1‐AP); Flag antibody was purchased from Sigma (F3165); AKT and p‐AKT~473~ were obtained from Cell Signaling Technology (4691 and 4051); pan‐PI3K inhibitor LY294002 was purchased from MedChemExpress (HY‐10108); DMEM was obtained from Gibco (12100046); FBS was acquired from Hyclone (SH30070); and Matrigel was obtained from Corning (356237).

2.2. Cell culture and hepatocellular carcinoma samples {#cas14331-sec-0004}
------------------------------------------------------

Cells (MHCC‐97H, YY‐8103, Huh7) used in this study were cultured in DMEM supplemented with 10% FBS and 1% antibiotics at 37°C and in 5% CO~2~.[14](#cas14331-bib-0014){ref-type="ref"} HCC tissues and paired normal tissues were collected from 220 patients at the Eastern Hepatobiliary Surgery Hospital (EHBH), Second Military Medical University (Shanghai, China). After surgical excision, all tissues were promptly frozen in liquid nitrogen and stored at −80°C. Informed written consent was obtained from all patients. All experiments were approved by the hospital\'s ethics committee.

2.3. Animals {#cas14331-sec-0005}
------------

Five‐week‐old male BALB/c mice were housed under standard conditions. Animal protocols, based on the SIBS Guide for the Care and Use of Laboratory Animal were complied with, and the study was approved by the Animal Care and Use Committee of the Shanghai Institutes for Biological Sciences.

2.4. Immunohistochemistry {#cas14331-sec-0006}
-------------------------

Paraffin‐embedded HCC tissues (n = 220) and normal tissues (n = 220) were analyzed by immunohistochemistry (IHC) as described previously.[15](#cas14331-bib-0015){ref-type="ref"} After deparaffinization, rehydration, antigen retrieval and blocking of endogenous peroxidases, sections were washed three times in 0.01 mol/L PBS for 5 minutes and blocked for 1 hour in 5% normal goat serum, followed by incubation with anti--EVA1 (1:100) antibody at 4°C overnight. After brief washes in PBS, corresponding secondary antibodies were added, and samples were further incubated at 37°C for 1 hour. Slides were visualized after DAB staining. The staining intensity of tumor cells was scored on a scale of 0‐3, with 0 indicating no staining, and 1 indicating weak staining, 2 moderate staining and 3 strong staining intensity.[16](#cas14331-bib-0016){ref-type="ref"}

2.5. RT‐PCR analysis {#cas14331-sec-0007}
--------------------

Total RNA was extracted from HCC samples and cells using TRIzol Reagent (Invitrogen). Reverse transcription and PCR were performed as previously reported.[15](#cas14331-bib-0015){ref-type="ref"} A total of 3 μg RNA was used as template for first‐strand cDNA synthesis, according to the manufacturer\'s instructions (M‐MLV Reverse transcriptase, Promega). Real‐time PCR (RT‐PCR) experiments were performed with Hieff qPCR SYBR Green Master Mix (Yeasen) in PIKOREAL 96 (Thermo scientific). Amplification reactions were performed in a 10‐μL volume.

The PCR primers used in this study are shown (Table [1](#cas14331-tbl-0001){ref-type="table"}). GAPDH was used as internal control (normalizer).

###### 

Primer sequence

  Gene        Forward                                                      Reverse
  ----------- ------------------------------------------------------------ ------------------------------------------------------------
  EVA1        TGCTCTAGAATGTATGGCAAGAGCCCCGCGCTTG                           CCATCGATCGTCTGTATCTTCCACAAAAACAGAG
  EVA1‐SH1    CCGGGTTCGACGACAATGGGACATACTCGAGTATGTCCCATTGTCGTCGAACTTTTTG   AATTCAAAAAGTTCGACGACAATGGGACATACTCGAGTATGTCCCATTGTCGTCGAAC
  EVA1‐SH2    CCGGGAAACTGCAGTTCGACGACAACTCGAGTTGTCGTCGAACTGCAGTTTCTTTTTG   AATTCAAAAAGAAACTGCAGTTCGACGACAACTCGAGTTGTCGTCGAACTGCAGTTTC
  EVA1‐RT     TTAATGGGACAGATGCTCGGT                                        AAGACACCCGGTCCTTAAACC
  GAPDH‐RT    ATGACCCCTTCATTGACCTCA                                        GAGATGATGACCCTTTTGGCT
  PIK3R3‐RT   TACAATACGGTGTGGAGTATGGA                                      TCATTGGCTTAGGTGGCTTTG
  GAB1‐RT     GATGGTTCGTGTTACGCAGTG                                        CGCTGTCTGCTACCAAGTAGAA
  ERBB3‐RT    GGTGATGGGGAACCTTGAGAT                                        CTGTCACTTCTCGAATCCACTG
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2.6. RNA sequencing {#cas14331-sec-0008}
-------------------

Five replicates of RNA derived from EVA1 of depleted YY‐8103 and scramble control were used for RNA sequencing (RNA‐seq). Analysis was performed using limma (Version 3.34.7, <https://bioconductor.org/packages/release/bioc/html/limma.html>).

2.7. Plasmid transfection {#cas14331-sec-0009}
-------------------------

Lentiviral constructs expressing EVA1 and shRNA targeting EVA1 expression were constructed as previously reported.[14](#cas14331-bib-0014){ref-type="ref"} Therefore, cells were infected with Plko.1‐shRNA or p23‐ZsGreen‐EVA1 lentivirual particles to silence or overexpress EVA1, respectively. Silenced cells were selected by puromycin treatment (2 μg/mL) for 3 days and expanded. Overexpressed cells were sorted by flow cytometry. Sequences of primers were shown in Table [1](#cas14331-tbl-0001){ref-type="table"}.

2.8. Western blot analysis {#cas14331-sec-0010}
--------------------------

Western blot was performed as described.[16](#cas14331-bib-0016){ref-type="ref"} Cultured cells or tissues were first lysed in RIPA buffer for 15 minutes on ice. Cell lysates were clarified after centrifugation at 20 800 *g* for 15 minutes. Protein concentration was determined using Bradford Reagent (Bio‐Rad). Equal amounts of protein lysates were resolved by SDS‐PAGE. After transferring membranes, the samples were immunoblotted with indicated primary and corresponding secondary antibodies.

2.9. Cell growth {#cas14331-sec-0011}
----------------

To assess the proliferation ability of HCC cells, crystal violet and MTT assays were performed as previously described.[15](#cas14331-bib-0015){ref-type="ref"}, [17](#cas14331-bib-0017){ref-type="ref"} MHCC‐97H, YY‐8103 and Huh7 cells (1000/well) were seeded in 96‐well plates for various durations; 5 mg/mL MTT (20 μL/well) was added to each well and incubated for 4 hours. HCC cells were seeded at a density of 5 × 10^3^ cells/well in six‐well plates. After 7 days of cell culture, medium was removed and cells were stained with 1 mL 0.1% crystal violet solution in 20% methanol.

2.10. Transwell assay {#cas14331-sec-0012}
---------------------

To evaluate the migration and invasion of HCC cells, transwell assays were performed as described.[14](#cas14331-bib-0014){ref-type="ref"} For this, 2 × 10^5^ cells were added to the upper chamber coated with or without Matrigel (BD). FBS‐containing medium was loaded into bottom wells to promote migration and invasion. Cells were incubated for 36 hours. Three microscopic fields were randomly selected and cells were counted.

2.11. Tumorigenesis in vivo {#cas14331-sec-0013}
---------------------------

Resuspended cells were injected subcutaneously into both flanks of 5‐week‐old male nude mice (1 × 10^6^ cells per injection) in accordance with AAALAC criteria. Tumor volume (cm^3^) was measured every 4 days from day 7 after injection, and tumor weight was measured after the mice were killed.

2.12. In vivo metastasis assay {#cas14331-sec-0014}
------------------------------

Stably‐transduced YY‐8103 cells and respective scramble control were labeled with luciferase. A 200‐μL aliquot of PBS solution containing 1 × 10^6^ cells was delivered into 5‐week‐old nude mice by tail vein injection. Distant seeding lesions were monitored weekly via D‐luciferin staining (150 mg/kg) using an in vivo imaging system (Xenogen). After injection of D‐luciferin solution for 2 minutes, mice were placed into a light‐tight chamber and monitored using a CCD camera system. The fluorescence signal from the luciferase‐containing metastatic area was quantified using Living Image software.

2.13. In vivo metastasis assay using intrahepatic injection model {#cas14331-sec-0015}
-----------------------------------------------------------------

Intrahepatic injection was performed as previously described.[18](#cas14331-bib-0018){ref-type="ref"} Five‐week‐old nude mice were injected i.p. with 50 mg/kg sodium pentobarbital. Thereafter, the left lobe of mice liver was placed outside the body through a subcostal incision. A total of 5 × 10^5^ cells were injected into hepatic lobes of nude mice. The presence of luciferase‐containing HCC cells was confirmed 3 days after surgery, using the Living Image system (Xenogen). The mice were killed 8 or 12 weeks later. Metastases in injection and non--injection lobes were counted accordingly.

2.14. Statistical analysis {#cas14331-sec-0016}
--------------------------

Survival curves were plotted according to the Kaplan‐Meier method and analyzed by log‐rank test. Statistical analyses were performed using GraphPad Prism 5 and SPSS 22 (IBM) software. The results were representative of at least three independent experiments performed in triplicate (expressed as the means ± SD). The data were analyzed using Student\'s *t* test. The criterion for significance was *P* \< .05 for all comparisons.

3. RESULTS {#cas14331-sec-0017}
==========

3.1. Expression pattern and clinical significance of epithelial V‐like antigen 1 in hepatocellular carcinoma {#cas14331-sec-0018}
------------------------------------------------------------------------------------------------------------

To determine the expression level of EVA1 in HCC, we performed RT‐PCR to evaluate the EVA1 mRNA levels in a series of HCC tissues and matched normal hepatic tissues. EVA1 transcript levels were upregulated in 82.1% (32/39) of HCC tissues (Figure [1](#cas14331-fig-0001){ref-type="fig"}A). Furthermore, nine pairs of HCC tissues and adjacent normal tissues were randomly selected to detect EVA1 protein yields by western blotting. Increased EVA1 levels were found in almost all nine HCC tissues when compared with their respective normal counterparts (Figure [1](#cas14331-fig-0001){ref-type="fig"}B). To further confirm the expression pattern of EVA1 in HCC, the expression of EVA1 was examined by IHC staining in tissue microarrays. Consistently, the expression levels of EVA1 were significantly increased in HCC‐derived tissues compared with normal tissues (*P* = .0005; Figure [1](#cas14331-fig-0001){ref-type="fig"}C,D), The EVA1 expression profile in HCC was similar to the one observed in lung adenocarcinoma.[9](#cas14331-bib-0009){ref-type="ref"} Moreover, we analyzed the relationship between EVA1 expression and the prognosis of 220 HCC patients. In this context, we observed that high EVA1 expression levels were closely associated with poor recurrence‐free survival (*P* \< .001) and overall survival (*P* = .001) of HCC patients (Figure [1](#cas14331-fig-0001){ref-type="fig"}E,F).

![Epithelial V‐like antigen 1 (EVA1) expression was upregulated in hepatocellular carcinoma (HCC) and associated with poor prognosis of patients. A, EVA1 mRNA levels in 39 pairs of tumor samples (T) and their adjacent non--carcinoma normal tissues (N) were examined by RT‐PCR. B, EVA1 levels in nine pairs of N, T and portal vein tumor thrombus (PVTT) tissues (P), derived from HCC patients, were determined by western blotting. C, Representative immunohistochemistry staining of EVA1 in paired N and T tissues from 2 HCC patients, D, H‐scores of EVA1 protein in N (N = 220) and T (n = 220) HCC tissues (*P* = .0005), E, F, The recurrence‐free survival (EVA1 high, n = 110; EVA1 low, n = 110; *P* \< .001) and overall survival (EVA1 high, n = 110; EVA1 low, n = 110; *P* = .001) of patients with high and low EVA1 expression](CAS-111-1500-g001){#cas14331-fig-0001}

According to the level of EVA1 expression, we divided HCC patients into two groups: EVA1 low (score \< 79) and EVA1 high (score ≥ 79) gene expression. The relationship between EVA1 expression and the clinicopathological features of 220 HCC patients were further analyzed. As shown in Table [2](#cas14331-tbl-0002){ref-type="table"}, EVA1 expression level was positively associated with the presence of α‐fetoprotein (*P* = .004), tumor diameter (*P* = .003), number of tumors (*P* = .012), tumor capsulation (*P* = .043), portal vein tumor thrombus (PVTT; *P* = .001) and microvascular invasion (*P* = .019; Table [2](#cas14331-tbl-0002){ref-type="table"}). Cox\'s multivariate proportional hazards model could demonstrate that some of the following factors were independent predictors of overall survival: EVA1 \> 79 (hazard ratio \[HR\]: 2.120, 95% confidence interval \[CI\]: 1.358‐3.309, *P* = .01), presence of PVTT (HR: 3.044, 95% CI: 1.783‐5.198, *P* \< .001) and microvascular invasion (HR: 2.969, 95% CI: 1.925‐4.580, *P* \< .001; Table [3](#cas14331-tbl-0003){ref-type="table"}). Furthermore, the following factors were considered independent predictors of tumor recurrence in HCC patients: EVA1 \> 79 (HR: 3.347, 95% CI: 2.196‐5.102, *P* \< .001), alanine aminotransferase (ALT) \> 44 U/L (HR: 1.717,95% CI: 1.179‐2.502, *P* = .005) and presence of microvascular invasion (HR: 2.502, 95% CI: 1.713‐3.652, *P* \< .001; Table [4](#cas14331-tbl-0004){ref-type="table"}). These data revealed that EVA1 may serve as a prognostic marker in HCC and may act as a tumor promoter in HCC progression and metastasis.

###### 

Correlation between EVA1 expression and clinicopathological characteristics

  Variables                 Number   EVA1, n (%)   *P*‐value     
  ------------------------- -------- ------------- ------------- ----------
  Age, y                                                         .590
  \<50                      112      58 (52.7%)    54 (49.1%)     
  ≥50                       108      52 (47.3%)    56 (50.9%)     
  Sex                                                            .491
  Male                      199      98 (89.1%)    101 (91.8%)    
  Female                    21       12 (10.9%)    9 (8.2%)       
  HBsAg                                                          .810
  Negative                  19       9 (8.2%)      10 (9.1%)      
  Positive                  201      101 (91.8%)   100 (90.9%)    
  AFP, ng/mL                                                     **.004**
  \<400                     123      72 (65.5%)    51 (46.4%)     
  ≥400                      97       38 (34.5%)    59 (53.6%)     
  Total bilirubin, μmol/L                                        .736
  ≤17.1                     176      89 (80.9%)    87 (79.1%)     
  \>17.1                    44       21 (19.1%)    23 (20.9%)     
  Albumin, g/L                                                   .701
  \<35                      7        3 (2.7%)      4 (3.6%)       
  ≥35                       213      107 (97.3%)   106 (96.4%)    
  ALT, U/L                                                       .579
  ≤44                       136      66 (60.0%)    70 (63.6%)     
  \>44                      84       44 (40.0%)    40 (36.4%)     
  Tumor diameter, cm                                             **.003**
  \<5                       77       49 (44.5%)    28 (25.5%)     
  ≥5                        143      61 (55.5%)    82 (74.5%)     
  Number of tumors                                               **.012**
  Single                    199      105 (95.5%)   94 (85.5%)     
  Multiple                  21       5 (4.5%)      16 (14.5%)     
  Tumor capsulation                                              **.043**
  No                        106      60 (54.5%)    46 (41.8%)     
  Incomplete                51       18 (16.4%)    33 (30.0%)     
  Complete                  63       32 (29.1%)    31 (28.2%)     
  PVTT                                                           **.001**
  Negative                  184      101 (91.8%)   83 (75.5%)     
  Positive                  36       9 (8.2%)      27 (24.5%)     
  Microvascular invasion                                         **.019**
  Negative                  133      75 (68.2%)    58 (52.7%)     
  Positive                  87       35 (31.8%)    52 (47.3%)     

*P* \< .05 is shown in bold.

Abbreviations: AFP, α‐fetoprotein; ALT, Alanine Aminotransferase; EVA1, epithelial V‐like antigen 1; HBsAg, Hepatitis B surface antigen; PVTT, portal vein tumor thrombus.
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###### 

Univariate and multivariable analysis for overall survival

  Variables                          Univariate analysis   Multivariate analysis                         
  ---------------------------------- --------------------- ----------------------- --------------------- ----------
  Age, ≥50 y                         0.920 (0.608‐1.392)   .694                                           
  Sex, male                          1.279 (0.619‐2.645)   .506                                           
  HBsAg, positive                    1.441 (0.629‐3.299)   .387                                           
  AFP, ≥400 ng/mL                    1.798 (1.173‐2.756)   **.007**                1.342 (0.862‐2.091)   .193
  Total bilirubin, \>17.1 μmol/L     1.176 (0.701‐1.972)   .540                                           
  Albumin, ≥35 g/L                   0.700 (0.257‐1.909)   .486                                           
  ALT, \>44 U/L                      1.210 (0.795‐1.841)   .375                                           
  Tumor diameter, ≥5 cm              2.610 (1.547‐4.401)   **\<.001**              1.579 (0.889‐2.805)   .119
  Number of tumors, multiple         1.259 (0.653‐2.431)   .492                                           
  Tumor capsulation, full                                                                                 
  Tumor capsulation, incomplete      1.195 (0.720‐1.984)   .490                                           
  Tumor capsulation, no              1.180 (0.716‐1.944)   .517                                           
  PVTT, positive                     3.044 (1.783‐5.198)   **\<.001**              2.033 (1.166‐3.545)   **.012**
  Microvascular invasion, positive   2.969 (1.925‐4.580)   **\<.001**              1.966 (1.207‐3.201)   **.007**
  EVA1, high expression              2.120 (1.358‐3.309)   **.001**                1.636 (1.033‐2.589)   **.036**

*P* \< .05 is shown in bold.

Abbreviations: AFP, α‐fetoprotein; ALT, Alanine Aminotransferase; HBsAg, Hepatitis B surface antigen; PVTT, portal vein tumor thrombus.
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###### 

Univariate and multivariable analysis for disease‐free survival

  Variables                          Univariate analysis   Multivariate analysis                         
  ---------------------------------- --------------------- ----------------------- --------------------- ------------
  Age, ≥50 y                         1.206 (0.829‐1.754)   .328                                           
  Sex, male                          1.709 (0.832‐3.511)   .145                                           
  HBsAg, positive                    1.361 (0.662‐2.796)   .402                                           
  AFP, ≥400 ng/mL                    1.614 (1.110‐2.348)   **.012**                1.173 (0.791‐1.738)   .428
  Total bilirubin, \>17.1 μmol/L     1.015 (0.630‐1.633)   .953                                           
  Albumin, ≥35 g/L                   0.542 (0.134‐2.196)   .391                                           
  ALT, \>44 U/L                      1.717 (1.179‐2.502)   **.005**                1.791 (1.179‐2.721)   **.006**
  Tumor diameter, ≥5 cm              2.234 (1.443‐3.458)   **\<.001**              1.315 (0.803‐2.154)   .277
  Number of tumors, multiple         1.936 (1.138‐3.291)   **.015**                1.219 (0.680‐2.183)   .506
  Tumor capsulation, full                                                                                 
  Tumor capsulation, incomplete      1.551 (0.982‐2.450)   .060                                           
  Tumor capsulation, no              1.596 (1.019‐2.500    **.041**                1.064 (0.619‐1.829)   .822
  PVTT, positive                     2.083 (1.239‐3.502)   **.006**                1.321 (0.664‐2.629)   .427
  Microvascular invasion, positive   2.502 (1.713‐3.652)   **\<.001**              1.888 (1.216‐2.932)   **.005**
  EVA1, high expression              3.347 (2.196‐5.102)   **\<.001**              2.697 (1.710‐4.253)   **\<.001**

*P* \<.05 is shown in bold.

Abbreviations: AFP, α‐fetoprotein; ALT, alanine aminotransferase; HBsAg, Hepatitis B surface antigen; PVTT, portal vein tumor thrombus.
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3.2. Epithelial V‐like antigen 1 overexpression promoted the proliferation, invasion and migration of hepatocellular carcinoma cells in vitro {#cas14331-sec-0019}
---------------------------------------------------------------------------------------------------------------------------------------------

Based on the clinical data, we speculated that EVA1 may have an effect on the growth, invasion and metastasis of HCC cells. Thus, we transfected MHCC‐97H, YY‐8103 and Huh7 cell lines with EVA1 overexpression vector (or empty control vector) to study the function of EVA1. The endogenous expression of EVA1 in HCC cell lines was detected by western blotting (Figure [S1](#cas14331-sup-0001){ref-type="supplementary-material"}A). The efficiency of EVA1 overexpression was evaluated by western blotting (Figures [2](#cas14331-fig-0002){ref-type="fig"}A and [S1](#cas14331-sup-0001){ref-type="supplementary-material"}B). As expected, EVA1 overexpression significantly increased cell growth, which was revealed by MTT (*P* \< .005; Figures [2](#cas14331-fig-0002){ref-type="fig"}B and [S1](#cas14331-sup-0001){ref-type="supplementary-material"}C) and colony formation assays (*P* \< .05; Figures [2](#cas14331-fig-0002){ref-type="fig"}C and [S1](#cas14331-sup-0001){ref-type="supplementary-material"}D). Remarkably, forced expression of EVA1 remarkably promoted invasion (*P* \< .005; Figures [2](#cas14331-fig-0002){ref-type="fig"}D and [S1](#cas14331-sup-0001){ref-type="supplementary-material"}E) and migration (*P* \< .001; Figures [2](#cas14331-fig-0002){ref-type="fig"}E and [S1](#cas14331-sup-0001){ref-type="supplementary-material"}F) of HCC cells in vitro. These results were consistent with the increased EVA1 expression in clinical HCC samples.

![Epithelial V‐like antigen 1 (EVA1) overexpression promoted growth, colony formation, invasion and migration of hepatocellular carcinoma (HCC) cells in vitro. A, Western blotting was performed to examine the protein levels of EVA1 in stably‐transduced HCC cells. B, The effects of EVA1 overexpression on the viability of Huh7 and YY‐8103 cells were evaluated using MTT assays. C, Crystal violet assay was used to determine the colony formation ability in HCC cells upon EVA1 overexpression. D, E, Effects of EVA1 overexpression in the invasion and migration of HCC cells were examined by transwell assay. The data are presented as the mean ± SEM. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001](CAS-111-1500-g002){#cas14331-fig-0002}

3.3. Knockdown of epithelial V‐like antigen 1 expression decreased the growth and migration of hepatocellular carcinoma cells in vitro {#cas14331-sec-0020}
--------------------------------------------------------------------------------------------------------------------------------------

To further confirm the effects of EVA1 in HCC cells, we knocked down EVA1 expression in YY‐8103 and Huh7 cells (Figure [3](#cas14331-fig-0003){ref-type="fig"}A). Based on MTT assay, depletion of EVA1 significantly decreased cell proliferation (*P* \< .005; Figure [3](#cas14331-fig-0003){ref-type="fig"}B). Consistently, reduction in colony formation was observed in EVA1 knockdown YY‐8103 and Huh7 cells (*P* \< .005; Figure [3](#cas14331-fig-0003){ref-type="fig"}C). Furthermore, EVA1 knockdown remarkably decreased HCC cell invasion (*P* \< .05) and migration (*P* \< .005; Figure [3](#cas14331-fig-0003){ref-type="fig"}D,E). These in vitro results revealed that EVA1 knockdown can effectively inhibit growth, invasion and migration of HCC cells.

![Epithelial V‐like antigen 1 (EVA1) knockdown inhibited growth, colony formation, invasion and migration in hepatocellular carcinoma (HCC) cells in vitro. A, Western blotting was performed to examine the protein level of EVA1 in HCC cells after knockdown of EVA1 expression. B, MTT assay was used to assess the effect of EVA1 depletion on the viability of YY‐8103 and Huh7 cells. C, Effects of EVA1 knockdown on the colony formation of HCC cells as assessed by crystal violet staining. D, E, Invasion and migration of HCC cells upon knockdown of EVA1 expression were examined by transwell assay. The data are presented as mean ± SEM. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001](CAS-111-1500-g003){#cas14331-fig-0003}

3.4. Epithelial V‐like antigen 1 promoted tumorigenesis of hepatocellular carcinoma cells in vivo {#cas14331-sec-0021}
-------------------------------------------------------------------------------------------------

To further clarify whether EVA1 could also promote the proliferation of HCC cells in vivo, scramble control and EVA1 knockdown YY‐8103 and Huh7 cells were injected into the flanks of nude mice, respectively, and tumor growth was monitored (Figure [4](#cas14331-fig-0004){ref-type="fig"}A,B). Tumors generated by EVA1 knockdown YY‐8103 and Huh7 cells grew slower and were smaller than those generated by scramble control cells (*P* \< .005; Figure [4](#cas14331-fig-0004){ref-type="fig"}A,B). The H&E staining of the xenograft and the immunohistochemical staining of EVA1 in tumors are shown in Figure [S2](#cas14331-sup-0002){ref-type="supplementary-material"}A,B. These data suggested that downregulation of EVA1 impaired tumorigenesis of HCC cells in vivo, which was consistent with the function of EVA1 in vitro.

![Epithelial V‐like antigen 1 (EVA1) knockdown suppressed the tumorigenesis and metastasis of hepatocellular carcinoma (HCC) cells in vivo. A, B, Imaging, growth curves (cm^3^) and weight (g) of the tumors generated after injection of scramble or EVA1 knockdown YY‐8103 cells and Huh7 cells. C, Imaging, photon counts and survival curve of the intrahepatic metastasis of scramble and EVA1 knockdown YY‐8103 cells. D, Foci number of injection and non--injection lobes of intrahepatic metastasis mouse model, using stably‐transduced HCC cells. E, Fluorescence of metastases generated by distant seeding after tail vein injection with EVA1 knockdown or scramble HCC cells in mice. Each bar represents the mean ± SD. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001](CAS-111-1500-g004){#cas14331-fig-0004}

3.5. Epithelial V‐like antigen 1 promoted metastasis of hepatocellular carcinoma cells in vivo {#cas14331-sec-0022}
----------------------------------------------------------------------------------------------

Subsequently, we speculated whether EVA1 could enhance the metastasis of HCC cells in vivo. We used an intrahepatic metastasis mouse model to identify this hypothesis. As shown in Figure [4](#cas14331-fig-0004){ref-type="fig"}C, a lower foci content was detected on both injected and non--injected lobes of the nude mice injected with EVA1 knockdown YY‐8103 cells, compared with those injected with scramble control cells. Furthermore, the mice bearing tumors generated by EVA1 knockdown YY‐8103 cells had longer survival than control mice (*P* = .04; Figure [4](#cas14331-fig-0004){ref-type="fig"}C). The H&E staining of the liver and the immunohistochemical staining of EVA1 within the foci are shown in Figure [S2](#cas14331-sup-0002){ref-type="supplementary-material"}C, which further confirmed the tumor foci and EVA1 knockdown. These results suggested that EVA1 knockdown prolonged the survival time of tumor‐bearing mice by suppressing metastasis of HCC cells.

Furthermore, a tail vein injection model was used to explore the effect of EVA1 on distant seeding of HCC cells. Five weeks after injection, many metastatic foci were detected in the mice injected with YY‐8103 scramble control cells, while fewer foci were observed in mice injected with EVA1 knockdown YY‐8103 cells (Figure [4](#cas14331-fig-0004){ref-type="fig"}E). Consistent with in vitro study, these results demonstrated that EVA1 knockdown inhibited metastasis of HCC cells in vivo. Taken together, these finding suggested that EVA1 may act as a metastasis promotor in HCC.

3.6. Epithelial V‐like antigen 1 activated ERBB‐PI3K‐AKT signaling in hepatocellular carcinoma cells {#cas14331-sec-0023}
----------------------------------------------------------------------------------------------------

To investigate the underlying mechanism, RNA‐seq was used to identify the signaling pathways influenced by EVA1. The hierarchical clustering generated from expression of differentially expressed mRNA from EVA1 knockdown YY‐8103 cells and scramble control cells disclosed distinct expression patterns of multiple mRNA between the two groups (Figure [5](#cas14331-fig-0005){ref-type="fig"}A). To identify pathways affected by EVA1, we used KEGG pathway enrichment to analyze the data from RNA‐seq (Figure [5](#cas14331-fig-0005){ref-type="fig"}B). We identified expression of several fundamental genes in Notch, ERBB and TGF‐b signaling pathways revealed by RNA‐seq, and ERBB signaling was chosen for further study because the expression pattern of the key genes in this pathway, including ERBB3, PIK3R3 and GAB1, was consistent with our findings. In addition, ERBB3 was reported to be a promotor of hepatocarcinogenesis.[19](#cas14331-bib-0019){ref-type="ref"} The mRNA expressions of PIK3R3, GAB1 and ERBB3 genes in ERBB pathway were significantly reduced in EVA1 knockdown YY‐8103 cells when compared with scramble control cells. Consistently, EVA1‐overexpressing YY‐8103 cells exhibited a remarkable increase in mRNA expression of these genes (Figure [5](#cas14331-fig-0005){ref-type="fig"}C). Furthermore, we found that overexpression of EVA1 significantly elevated the level of p‐AKT (Ser473) in HCC cells (Figure [5](#cas14331-fig-0005){ref-type="fig"}D), a well‐known marker of PI3K activation. In contrast, knockdown EVA1 expression remarkably decreased the level of p‐AKT (Ser473) in HCC cells (Figure [5](#cas14331-fig-0005){ref-type="fig"}E). To explore their relationship in the clinic, we examined the level of p‐AKT (Ser473) and EVA1 in nine pairs of HCC samples (N,T,P) and their expression was quantified by Image J software. The level of p‐AKT (Ser473) and EVA1 were upregulated in all nine pairs of HCC samples (Figure [5](#cas14331-fig-0005){ref-type="fig"}F, left). Furthermore, a positive correlation between EVA1 expression and the level of p‐AKT (Ser473) was observed (Figure [5](#cas14331-fig-0005){ref-type="fig"}F, right, *P*‐value \< .0001, *r* ^2^ = .91). Taken together, all these results suggested that EVA1 activated the ERBB‐PI3K‐AKT cascade.

![Epithelial V‐like antigen 1 (EVA1) activates the ERBB3‐PI3K‐AKT signaling pathway in hepatocellular carcinoma (HCC) cells. A, A Hierarchical clustering generated from differentially expressed mRNA upon knockdown of EVA1 expression in YY‐8103 cells and scramble cells group, B, KEGG enrichment plot based on RNA‐seq results, C, RT‐PCR was performed to validate the effect of EVA1 on the ERBB‐PI3K‐AKT pathway in YY‐8103 cells, D, E, Overexpression and knockdown of EVA1, respectively, activated and suppressed the level of AKT phosphorylation in YY‐8103 and Huh7 cells, as assessed by western blotting. F, Western blotting analysis of EVA1 and AKT phosphorylation in nine pairs of HCC samples (left) abd linear regression analysis showing the positive correlation between p‐AKT~473~ and EVA1 (right)](CAS-111-1500-g005){#cas14331-fig-0005}

3.7. LY294002, a potent PI3K inhibitor, inhibited AKT phosphorylation and rescued hepatocellular carcinoma phenotype driven by epithelial V‐like antigen 1 overexpression {#cas14331-sec-0024}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To further evaluate the involvement of ERBB‐PI3K‐Akt signaling in the tumor‐promoting role of EVA1 in HCC cells, we examined whether blockade of PI3K could rescue the phenotype of EVA1‐overexpression HCC cells. Therefore, LY294002, a PI3K inhibitor,[20](#cas14331-bib-0020){ref-type="ref"} was employed. LY294002 treatment significantly reduced AKT phosphorylation in EVA1‐overexpression HCC cells (Figures [6](#cas14331-fig-0006){ref-type="fig"}A and [S3](#cas14331-sup-0003){ref-type="supplementary-material"}A). Moreover, the inhibition of HCC cell growth, invasion and migration by EVA1 overexpression was restored upon inhibitor treatment (Figures [6](#cas14331-fig-0006){ref-type="fig"}B‐E and [S3](#cas14331-sup-0003){ref-type="supplementary-material"}B‐E). These observations indicated that the PI3K‐AKT pathway mediated the tumor‐promoting effect of EVA1.

![LY294002, a PI3K inhibitor, suppressed the level of AKT phosphorylation and rescued hepatocellular carcinoma (HCC) phenotype driven by epithelial V‐like antigen 1 (EVA1) overexpression. A, LY294002 suppressed the level of AKT phosphorylation in YY‐8103 and Huh7 cells with EVA1 overexpressing assessed by western blotting. B, MTT assays were used to evaluate the effects of suppressing the level of phosphorylation on the viability of YY‐8103 and Huh7 cells. C, Crystal violet assays were used to assess the effects of inhibiting AKT phosphorylation on the colony formation ability of HCC cells. D, Effects of suppressing the level of AKT phosphorylation on the invasion and migration (E) of HCC cells were evaluated by transwell assay. The data are presented as the mean ± SEM. \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001](CAS-111-1500-g006){#cas14331-fig-0006}

4. DISCUSSION {#cas14331-sec-0025}
=============

Epithelial V‐like antigen 1, also known as MPZL2, was first reported in thymus histogenesis.[5](#cas14331-bib-0005){ref-type="ref"} A later study demonstrated expression of EVA1 on cortical and medullary epithelial cell subsets and revealed a restricted pattern of expression on CD4‐CD8‐double negative cell subsets.[21](#cas14331-bib-0021){ref-type="ref"} Subsequent studies reported its involvement in mammary epithelial cell differentiation[12](#cas14331-bib-0012){ref-type="ref"} and hearing.[22](#cas14331-bib-0022){ref-type="ref"} However, its function in cancer remains largely unknown; it is reported in papillary thyroid cancer,[23](#cas14331-bib-0023){ref-type="ref"} lung cancer[9](#cas14331-bib-0009){ref-type="ref"} and glioblastoma[13](#cas14331-bib-0013){ref-type="ref"} but not in HCC. Therefore, we explored its function and mechanism in this malignancy in the present study.

Previous studies have indicated that EVA1 is overexpressed in papillary thyroid cancer[23](#cas14331-bib-0023){ref-type="ref"} and lung cancer.[24](#cas14331-bib-0024){ref-type="ref"} Similar to previous reports, the present study demonstrated that EVA1 expression was higher in human HCC tissues than in matched normal tissues. HCC patients with high EVA1 expression have worse prognoses and higher recurrence rates than those with low EVA1 expression. Moreover, based on multivariate analysis, the present study demonstrated that EVA1 overexpression, tumor diameter, positive PVTT and microvascular invasion were independent and significant risk factors for survival or recurrence. Taken together, the present study demonstrated that EVA1 could be a dependable biomarker of HCC.

Hepatocellular carcinoma tends to invade the intrahepatic vasculature, especially through the portal vein.[25](#cas14331-bib-0025){ref-type="ref"} Frequent intrahepatic and extrahepatic metastases of HCC are responsible for the poor clinical prognosis of HCC patients.[26](#cas14331-bib-0026){ref-type="ref"} Previous studies have indicated that EVA1 is essential for epithelial differentiation of immortalized human mammary epithelial cells.[12](#cas14331-bib-0012){ref-type="ref"} Additional work has reported that EVA1 may have a function in lung cancer development as a cell adhesion molecule.[8](#cas14331-bib-0008){ref-type="ref"} However, whether EVA1 has a metastatic function in cancer has not been confirmed. The present study revealed that EVA1 is capable of promoting invasion and migration of HCC cells. Furthermore, an intrahepatic metastasis mouse model was used to clarify the effect of EVA1 on intrahepatic metastasis, while a tail vein injection model was used to explore the effect of EVA1 on the distant seeding of HCC cells. Collectively, these data revealed that EVA1 promoted metastasis of HCC cells in vitro and in vivo. Taken together, here we confirmed that EVA1 has a significant promoting role in the hepatic metastases of HCC.

In this study, we explored the mechanism underlying the tumor‐promoting effect of EVA1 by RNA‐seq. The RNA‐seq analysis revealed that the function of EVA1 in HCC may be associated with the Notch signaling pathway, the TGF‐beta signaling pathway and the ERBB signaling pathway, which was consistent with previous studies reporting its relationship with Notch signaling.[27](#cas14331-bib-0027){ref-type="ref"} Here, we chose ERBB signaling for further study because the expression pattern of the key genes in this pathway was consistent with the observed phenotype. High expression of ERBB3 in certain human cancers led early on to the suggestion that it could be a therapeutic target.[28](#cas14331-bib-0028){ref-type="ref"} ERBB3 was reported to have an oncogenic role in HCC.[29](#cas14331-bib-0029){ref-type="ref"} The most fully studied target of ERBB3 is the p85 regulatory subunit of PI3K (PI3KR). Moreover, Jones et al[30](#cas14331-bib-0030){ref-type="ref"} found that both SH2 groups in each of the three PI3KR isoforms bound with moderate or high affinity at multiple sites in ERBB3, including PIK3R3. PIK3R3 is associated with the activation of the class IA PI3K complex, as one of its regulatory subunits.[31](#cas14331-bib-0031){ref-type="ref"} PIK3R3 promotes tumor growth or metastasis in esophageal squamous cell carcinoma,[32](#cas14331-bib-0032){ref-type="ref"} glioma,[33](#cas14331-bib-0033){ref-type="ref"} HCC,[31](#cas14331-bib-0031){ref-type="ref"}, [34](#cas14331-bib-0034){ref-type="ref"}, [35](#cas14331-bib-0035){ref-type="ref"} ovarian cancer,[36](#cas14331-bib-0036){ref-type="ref"} gastric cancer,[37](#cas14331-bib-0037){ref-type="ref"} colorectal cancer[38](#cas14331-bib-0038){ref-type="ref"} and pancreatic cancer.[39](#cas14331-bib-0039){ref-type="ref"} Another identified candidate gene in ERBB signaling is GAB1, a docking protein that recruits phosphatidylinositol‐3 kinase (PI‐3 kinase) and other effector proteins in response to the activation of many receptor tyrosine kinases.[40](#cas14331-bib-0040){ref-type="ref"} Here we found that EVA1 regulated the mRNA level of ERBB3, PIK3R3 and GAB1, the genes whose protein product existed in the ERBB signaling transduction complex, indicating its modulation of the ERBB‐PI3K‐AKT pathway. Consistently, the present study demonstrated that depletion of EVA1 expression significantly suppressed the level of AKT phosphorylation and EVA1 overexpression remarkably promoted the level of AKT phosphorylation in HCC cells, which further confirmed the impact on ERBB‐PI3K‐Akt signaling by EVA1. In addition, LY294002, a PI3K inhibitor, significantly reduced the level of AKT phosphorylation and inhibited HCC cell growth, invasion and migration in EVA1‐overexpressing cells, which rescued the phenotype induced by forced expression of EVA1. The accumulating evidence suggested that EVA1 exerted a tumor‐promoting effect via the ERBB‐PI3K‐AKT pathway. Protein interaction data from Uniprot (<https://www.uniprot.org>) revealed that EVA1 potentially interacts with ERBB1 and ERBB2.[41](#cas14331-bib-0041){ref-type="ref"} EVA1 is a transmembrane protein. In addition, ERBB3 itself has impaired tyrosine kinase activity and needs a dimerization partner to become phosphorylated and to acquire signaling potential. It is possible that EVA1 interacts with ERBB members to regulate downstream signaling. Further study is required to identify this interesting hypothesis.

It is noteworthy that the mRNA level of ERBB3, PIK3R3 and GAB1, the proteins in the ERBB3 signaling complex, was influenced by EVA1. The transcription of ERBB3 was regulated by several transcriptional factors, including SOX10[42](#cas14331-bib-0042){ref-type="ref"} and FoxO3a.[43](#cas14331-bib-0043){ref-type="ref"} It was reported that transcription of GAB1 could be regulated by RARα[44](#cas14331-bib-0044){ref-type="ref"} and several microRNA, such as miR‐150[45](#cas14331-bib-0045){ref-type="ref"} and miR‐29a‐3p.[46](#cas14331-bib-0046){ref-type="ref"} As for PIK3R3, its transcription was reported to be regulated by SREBP1c[47](#cas14331-bib-0047){ref-type="ref"} and TGF‐β signaling.[48](#cas14331-bib-0048){ref-type="ref"} Further research is needed to interpret the impact of EVA1 on the expression of ERBB3, PIK3R3 and GAB1.

In summary, the present study demonstrated the significant role of EVA1 in tumor progression, recurrence and prognosis of HCC, and further correlated these effects with an underlying mechanism involving the ERBB‐PI3K‐AKT pathway. As such, EVA1 acts as an oncogene by promoting tumor progression and metastasis in HCC. Taken together, we strongly believe that EVA1 is a potential prognostic indicator and molecular target for HCC therapies.
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